Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison Sells 2,117 Shares of Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison sold 2,117 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $14.93, for a total value of $31,606.81. Following the completion of the sale, the director now directly owns 19,104 shares in the company, valued at approximately $285,222.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Assembly Biosciences Stock Up 2.2 %

ASMB traded up $0.33 during midday trading on Friday, hitting $15.08. The stock had a trading volume of 2,271 shares, compared to its average volume of 19,694. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04. The business has a fifty day moving average of $13.60 and a 200 day moving average of $11.51.

Institutional Investors Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC purchased a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent SEC filing. 19.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ASMB. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, May 10th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.